• Nenhum resultado encontrado

Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center

N/A
N/A
Protected

Academic year: 2021

Share "Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center"

Copied!
6
0
0

Texto

Loading

Imagem

TABLE 2   (Cont.) Characteristics of disease status,  preparative regimens, and transplant-related issues.
Table 3 summarizes data regarding TRM: 9 out of 15 pa- pa-tients (60%) in the 90 days post-ASCT, 4 out of 15 (26.7%)  in the first year, 2 out of 15 patients (13.3%) in the third  year post-ASCT (p=0.136)

Referências

Documentos relacionados

Philadelphia chromosome-positive acute lymphoblastic leukemia rescued with a second allogeneic stem cell transplantation from a haploidentical mother after relapse following cord

Pericardial effusion and cardiac tamponade: clinical manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.. David

Patients submitted to hematopoietic stem cell transplants and those in the conditioning period of acute myeloid leukemia chemotherapy are at the highest risk of developing long

positive precursor B-cell acute lymphoblastic leukemia with positive minimal residual disease (0.32%) before conditioning treatment for hematopoietic stem cell transplantation..

Hematopoietic stem cell transplantation in children with acute leukemia: similar outcomes in recipients of umbilical cord blood versus marrow or peripheral blood stem cells from

Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute

The report describes the outcomes of patients with FLT3 internal tandem duplication positive acute myeloid leukemia who relapsed after allogeneic hematopoietic stem

The report describes the outcomes of patients with FLT3 internal tandem duplication positive acute myeloid leukemia who relapsed after allogeneic hematopoietic stem